Lyra Therapeutics (LYRA) EBT Margin (2021 - 2025)
Historic EBT Margin for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to 23924.0%.
- Lyra Therapeutics' EBT Margin fell 178388700.0% to 23924.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 3525.91%, marking a year-over-year increase of 101582700.0%. This contributed to the annual value of 4019.32% for FY2023, which is 353400.0% up from last year.
- Per Lyra Therapeutics' latest filing, its EBT Margin stood at 23924.0% for Q3 2025, which was down 178388700.0% from 4062.84% recorded in Q2 2025.
- Over the past 5 years, Lyra Therapeutics' EBT Margin peaked at 828.15% during Q4 2024, and registered a low of 129290.91% during Q4 2022.
- For the 5-year period, Lyra Therapeutics' EBT Margin averaged around 17262.52%, with its median value being 4217.67% (2024).
- In the last 5 years, Lyra Therapeutics' EBT Margin plummeted by -1242661900bps in 2022 and then skyrocketed by 1189217300bps in 2023.
- Lyra Therapeutics' EBT Margin (Quarter) stood at 5024.72% in 2021, then crashed by -2473bps to 129290.91% in 2022, then skyrocketed by 92bps to 10369.18% in 2023, then soared by 108bps to 828.15% in 2024, then plummeted by -2989bps to 23924.0% in 2025.
- Its EBT Margin was 23924.0% in Q3 2025, compared to 4062.84% in Q2 2025 and 4668.31% in Q1 2025.